Riedl Christopher C, Brader Peter, Zanzonico Pat, Reid Vincent, Woo Yanghee, Wen Bixiu, Ling C Clifton, Hricak Hedvig, Fong Yuman, Humm John L
Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):39-46. doi: 10.1007/s00259-007-0522-2. Epub 2007 Sep 5.
The purpose of this paper is to compare the uptake of two clinically promising positron emission tomography (PET) hypoxia targeting agents, (124)I-iodoazomycin galactopyranoside ((124)I-IAZG) and (18)F-fluoromisonidazole ((18)F-FMISO), by dynamic microPET imaging, in the same rats bearing liver tumors and peritoneal metastasis.
Morris hepatoma (RH7777) fragments were surgically implanted into the livers of four nude rats. Tumors formed in the liver and disseminated into the peritoneal cavity. Each rat had a total of two to three liver tumors and peritoneal metastasis measuring 10-15 mm in size. Animals were injected with (18)F-FMISO, followed on the next day (upon complete (18)F decay) by (124)I-IAZG. The animals were imaged in list mode on the microPET system from the time of injection of each tracer for 3 h and then again at 6 h and 24 h for the long-lived (124)I-IAZG tracer (4.2-day half-life). Micro computed tomography (CT) scans of each rat were performed for co-registration with the microPET scans acquired with a liver contrast agent, allowing tumor identification. Regions of interest (ROIs) were drawn over the heart, liver, muscle, and the hottest areas of the tumors. Time-activity curves (TACs) were drawn for each tissue ROI.
The (18)F-FMISO signal increased in tumors over the 3-h time course of observation. In contrast, after the initial injection, the (124)I-IAZG signal slowly and continuously declined in the tumors. Nevertheless, the tumor-to-normal-tissue ratios of (124)I-IAZG increased, but more slowly than those of (18)F-FMISO and as a result of the differentially faster clearance from the surrounding normal tissues. These pharmacokinetic patterns were seen in all 11 tumors of the four animals.
(18)F-FMISO localizes in the same intra-tumor regions as (124)I-IAZG. The contrast ratios (tumor/background) reach similar values for the two hypoxia tracers, but at later times for (124)I-IAZG than for (18)F-FMISO and, therefore, with poorer count statistics. As a consequence, the (18)F-FMISO images are of superior diagnostic image quality to the (124)I-IAZG images in the Morris hepatoma McA-R-7777 tumor model.
本文旨在通过动态微型正电子发射断层扫描(microPET)成像,比较两种具有临床应用前景的正电子发射断层扫描(PET)乏氧靶向剂,即(124)I-碘阿霉素半乳糖苷((124)I-IAZG)和(18)F-氟米索硝唑((18)F-FMISO)在同一患有肝肿瘤和腹膜转移的大鼠体内的摄取情况。
将莫里斯肝癌(RH7777)组织块手术植入四只裸鼠的肝脏。肿瘤在肝脏中形成并扩散至腹腔。每只大鼠共有两到三个大小为10 - 15毫米的肝肿瘤和腹膜转移灶。给动物注射(18)F-FMISO,次日((18)F完全衰变后)注射(124)I-IAZG。从注射每种示踪剂开始,在微型PET系统上以列表模式对动物进行3小时成像,然后在6小时和24小时再次成像,以观察半衰期为4.2天的长寿命(124)I-IAZG示踪剂。对每只大鼠进行微型计算机断层扫描(CT),以便与使用肝脏造影剂获取的微型PET扫描进行配准,从而识别肿瘤。在心脏、肝脏、肌肉以及肿瘤最热的区域绘制感兴趣区(ROI)。为每个组织ROI绘制时间 - 活性曲线(TAC)。
在3小时的观察过程中,肿瘤内的(18)F-FMISO信号增强。相比之下,初次注射后,肿瘤内的(124)I-IAZG信号缓慢且持续下降。然而,(124)I-IAZG的肿瘤与正常组织比值增加,但比(18)F-FMISO增加得慢,这是由于其从周围正常组织中清除得更快。在四只动物的所有11个肿瘤中均观察到这些药代动力学模式。
(18)F-FMISO与(124)I-IAZG定位于肿瘤内相同区域。两种乏氧示踪剂的对比率(肿瘤/背景)达到相似的值,但(124)I-IAZG达到该值的时间比(18)F-FMISO晚,因此计数统计结果较差。因此,在莫里斯肝癌McA-R-7777肿瘤模型中,(18)F-FMISO图像的诊断图像质量优于(124)I-IAZG图像。